AvenCell secures USD 112 million in Series B funding

Marc Nemitz Marc Nemitz | 23.10.2024

AvenCell plans to use USD 112 million in funding to further develop its switchable CAR-T cell therapy platform. The goal: safer and more flexible treatments for cancer and autoimmune diseases

Watertown, Massachusetts, October 22, 2024 - AvenCell Therapeutics, Inc., a clinical-stage cell therapy company, today announced the closing of a $112 million Series B financing. The financing round was led by Novo Holdings, accompanied by new investors including F-Prime Capital, Eight Roads Ventures Japan, Piper Heartland Healthcare Capital and NYBC Ventures, as well as founding investor Blackstone Life Sciences.

AvenCell Therapeutics, Inc. was founded in 2021 by Blackstone Life Sciences, Cellex Cell Professionals and Intellia Therapeutics. The startup is headquartered in Watertown, Massachusetts, with additional R&D and manufacturing sites in Dresden, Germany.

Funding to accelerate clinical validation

The funding is intended to accelerate the clinical validation of AvenCell's proprietary Universal Switchable CAR-T cell therapy platform. This platform enables CAR-T cells to be switched on and off after administration, which is expected to make the treatment of a broad range of hematologic malignancies and autoimmune diseases safer and more effective.

Our Universal Switchable CAR-T platform gives us unprecedented control and flexibility to develop safer and more effective cell therapy.

Andrew Schiermeier, CEO of AvenCell

AvenCell's current clinical programs include the autologous CAR-T cell candidate AVC-101 and the CRISPR-modified allogeneic cell candidate AVC-201, both of which target the CD123 antigen found on most acute myeloid leukemia (AML) cells. AvenCell has further pipeline projects that are expected to enter clinical trials in the next two years.

New investors and strengthening of the Management Board

In addition to the financing round, Michael Bauer of Novo Holdings and Nihal Sinha of F-Prime Capital will join AvenCell's Board of Directors. Both emphasize the importance of the switchable CAR-T technology as a game changer in cell therapy, especially with regard to safety and efficacy issues in difficult diseases such as AML.

Strategic focus and expansion

The funding will also be used to support AvenCell's clinical development and global expansion. AvenCell's platform aims to revolutionize the standard of cell therapy by providing a customizable, scalable and more efficient treatment for difficult-to-treat cancers and autoimmune diseases.


Like it? Please spread the word:


Newsletter

Startups, stories and stats from the German startup ecosystem straight to your inbox. Subscribe with 2 clicks. Noice.

LinkedIn Connect

Take care, give care

Did this news inform or entertain you? Then we would be happy if you tell your network about it.

Share on Linkedin Share on Facebook Share on Xing

FYI: English edition available

Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?

Go to English edition

FYI: Deutsche Edition verfügbar

Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?

Deutsche Edition öffnen

Similar posts